Searched for
NOVARTIS NAMES
Ahead of Market: 10 things that will decide stock market action on WednesdayIndian equity markets extended losses for a fourth straight session as broad-based selling in IT, banking, auto, and consumer stocks dragge...- Novartis India shares soar 20% as Swiss parent plans full exit in Rs 1,446 crore dealNovartis India shares surged nearly 18% after its Swiss parent announced the sale of its 70.68% stake for approximately Rs 1,446 crore. A c...
- Novartis names new board member after international boss steps downNovartis has appointed AbbVie executive Patrick Horber to its executive committee, the Swiss pharmaceuticals maker said on Wednesday, after...
- Novartis heart drug price may fall by 60% on generic rollouts"At least 30-40 generic brands are expected to hit the market next in a couple of weeks," said Hari Natarajan, managing director, Pronto Co...
- Cipla shares rise after Vysov anti-diabetic drug acquisitionCipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the ...
- Natco dares Novartis with new heart drugAccording to data from AIOCD PharmaTrac, an agency that closely tracks pharmaceutical sales, Vymada had sales of Rs 68.3 crore for December...
- 4 pharma companies under CCI scanner over price-fixingNovartis, Abbott among cos served notice for alleged cartelisation in diabetic drug.
- Delhi High Court quashes Cipla's appeal, says it can't market generics of Novartis' OnbrezThe court said it can't make a definitive conclusion that Novartis' imports of Onbrez were insufficient to meet the demands COPD patients f...
- Lupin to market Novartis' inhaler under Loftair brand nameAccording to IMS sales data, Lupin is ranked second with 12.4 per cent market share of the overall anti-asthma segment within the Indian ph...
- Onbrez case: Delhi High Court reserves decision on Novartis-Cipla patent disputeDelhi High Court has reserved its decision on a high-profile patent case that pitted Swiss drug maker Novartis against Cipla over its respi...
- Novartis gets USFDA nod for heart failure drugThe Swiss drug major said the USFDA's decision was based on results of a study on 8,442 patients, including 637 from India.
- Delhi High Court notice to Novartis on Cipla plea"We will not give you an interim order. We will hear it on an early date and dispose it of. Notice. Renotify on February 5," the bench said.
- Cipla moves Delhi High Court against restraint on its Indacaterol-based drugThe matter was mentioned before a bench of Justices Badar Durrez Ahmed and Sanjeev Sachdeva who directed that the plea be listed before the...
- Delhi High Court restrains Cipla from selling drug containing IndacaterolHC temporarily restrained Cipla from manufacturing, importing or selling any drug containing the chemical Indacaterol.
- HC reserves order on Novartis-Cipla drug disputeThe Delhi High Court has reserved its verdict on a dispute between pharma firms Novartis and Cipla over manufacturing of the drug Indacater...
- Cipla asks government to revoke Novartis' patent; launches its drugCipla has launched low-cost generic version of Novartis's respiratory drug Indacaterol while asking government to revoke patents over the m...
- Novartis India keeps fingers crossed as SC hears glivec patent caseThe Indian subsidiary of Swiss drug maker Novartis is making a final attempt at getting a patent for its anti-cancer drug Imatinib with the...
- Novartis fined $250 mn for discriminationA Novartis pharmaceuticals unit was ordered to pay $250 million in punitive damages to a group of 5,600 female employees after losing a gen...
- Lupin, Novartis end patent row for LotrelLupin has reached an out-ofcourt settlement with Swiss pharma major Novartis for the latter’s hypertension drug sold under the brand name L...
- Novartis in a soup over snapping deal with distributorIn a rare case of its kind, a magisterial court in Mumbai has ordered the police to register First Information Report against pharma major ...
Load More
